VEENENDAAL, The Netherlands, September 13 /PRNewswire/ --

-  Newly Independent Radiation Oncology Company Emerges as Industry 
Leader with Distinct Focus on Partnership, Innovation and Integration

Nucletron announced today the successful management buy-out from Delft
Instruments, creating an independent company fully dedicated to radiation
oncology. Since its inception in 1974, Nucletron has operated several
entities in the field of radiation oncology throughout the world. The
consolidation of the various entities into one, focused company further
establishes Nucletron in a leadership role in this rapidly changing field.
Collaborative partnerships, pioneering research and development of advanced
technological innovations will enable Nucletron to more effectively deliver
cancer treatment solutions globally and set the company apart within the
industry.

"The creation of an independent Nucletron is the result of the company's
success in the past two years," said David Imperiali, chief executive officer
of Nucletron. "Nucletron has a strong tradition of innovation in
radiotherapy, and the breadth of our capability positions the company well to
continue to make significant contributions to the treatment of cancer."

The previous company, under Delft Instruments, was created in 1994 by
merging Nucletron, the global leader in brachytherapy solutions, with the
Oldelft Simulix(TM) brand of radiation therapy simulation and imaging
technology. Additionally, in 2003, Nucletron integrated the Helax and
Theratronics treatment planning and management solutions, from MDS Nordion,
into its portfolio to create Oncentra(R) MasterPlan(TM) and Oncentra(R)
Information Management.

"Nucletron's ability to restructure itself, anticipate needs, and
incorporate new state-of-the-art products and services into our solutions
suite gives us the ability to create strong and long-lasting relationships
with our customers and partners," said Jeroen Cammeraat, chief operating
officer of Nucletron. "The new corporate structure gives us the flexibility
and agility to continue to develop world-class solutions for our customers
and partners, focused on improving patient care."

With more than 10 percent of its revenues invested in research and
development, Nucletron continuously seeks improvement of its existing product
range and creation of new treatment options that improve patients' quality of
care through curative and palliative treatment. The company's continued
efforts in R&D, both in-house and through partnerships with leading academic
institutions, have resulted in a strong and unique IP base.

Headquartered in The Netherlands, Nucletron delivers customized solutions
to more than 3,000 institutions in more than 120 countries, equating to
global sales of euro 120 million (US$160 million), with operating profit 
levels that rank in the upper quartile of the industry. Worldwide, Nucletron 
has offices in 16 countries, including a production and R&D facility in The
Netherlands, R&D centers in Uppsala, Sweden and Oslo, Norway and sales,
marketing, service and support operations in Europe, Asia, Australia and
North America.

The supervisory board of Nucletron will be chaired by Rob Westerhof, who
has held senior positions in Asia and in the USA for Philips Medical Systems
and Philips Electronics. Commenting on the spin-off, Westerhof stated, "I am
excited to join Nucletron's supervisory board. Being involved in the medical
business for more than 15 years in various positions throughout the world, I
trust that I can make a contribution. Nucletron represents a strong brand in
the world of oncology and related areas, and there are excellent
opportunities for expanding our market share. I am looking forward to working
with the new management team and further strengthening Nucletron."

About Nucletron

Nucletron is a knowledge-based leader in Radiation Oncology, working with
clinical teams to realize innovative solutions that improve patient care.
Nucletron strives to offer the best possible choice of radiation modalities
through integrated products, software and services. Critical to the Nucletron
philosophy is the establishment of close working relationships with
individual clinical teams - reconfiguring traditional boundaries between
customer and solution provider. Many Nucletron employees have clinical
experience delivering oncology care, providing an in-depth understanding of
the complex needs of clinicians. The investors in the independent Nucletron
company include AlpInvest Partners, Advent International, the Nucletron
Management and Employees. For more information, visit www.nucletron.com.

Web site: http://www.nucletron.com